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Purpose: Some patient subsets are at higher risk of sleep apnea, including patients with chronic
pain. However, it is unclear whether patients and their caregivers are aware of the possibly
increased risk of sleep apnea in this population. Chronic pain is often treated with opioids which
may decrease both the central respiratory drive and the patency of the upper airway, potentially
contributing to this sleep disorder. Using a self-reporting questionnaire approach in the chronic
pain population, this study surveyed patient and caregiver awareness surrounding the risk of sleep
apnea. In addition, we looked at the influence of opioid therapy on the prevalence of sleep apnea.
Participants and methods: Consecutive patients presenting to a pain clinic were invited to
participate anonymously in a survey that included the STOP-Bang sleep apnea questionnaire,
which assesses patients’ knowledge, testing, diagnosis, or treatment of sleep apnea and whether
their caregivers had discussed with them their increased risk of sleep apnea and opioid use.
Results: Among 305 participating patients, 58.2% (n=173) screened positive for sleep apnea.
Among the 202 patients on opioid therapy, 59.2% (116/202) were STOP-Bang positive (score
≥3). However, only 37.5% (n=72/173) of these patients had discussed their risk of sleep apnea
with a caregiver and only 30.7% (n=59) underwent testing. Against expectation, opioids did
not increase the prevalence of sleep apnea in our study population.
Conclusion: Chronic pain patients had a high risk of sleep apnea, regardless of opioid prescription. Most patients were unaware of their increased risk and denied undergoing the necessary
testing. Greater attention to screening, testing, and education for sleep apnea needs to be paid
in chronic pain patients, especially given the potentially dangerous ramifications of opioidinduced sleep apnea.
Keywords: sleep apnea, opioids, narcotics, STOP-Bang survey
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An estimated 100 million Americans suffer from chronic pain disorders.1 This number
includes patients with cancer and non-cancer pain. In the latter group, chronic noncancer pain (CNCP) patients can suffer from a wide variety of painful conditions such
as fibromyalgia, arthritis, and other inflammatory conditions, afflicting primarily an
older demographic.
Sleep apnea affects 2%–14% in community-screened normal populations, but has
a much higher prevalence in certain patient subgroups.2 Twenty to 90% of individuals
referred for sleep studies, a physician-selected cohort, are affected by sleep apnea.2,3
Males are three times more likely to experience sleep apnea.4 Further, the prevalence
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increases with age, especially in people more than 60 years
old, and with obesity.3,4
Sleep-disordered breathing has two major manifestations, central sleep apnea (CSA) or obstructive sleep apnea
(OSA). Hence, sleep apnea may be a consequence of central
depression of respiratory rate, amplitude, reflex responses,
and reduced brain arousability, as well as the function of
chemoreceptors that monitor changes in blood oxygen and
carbon dioxide levels.5 Alternatively, sleep apnea is due
to obstruction by soft tissues of the upper airway.6 Sleepdisordered breathing is associated with an increased risk
for cardiovascular and cerebrovascular disease, as well as
a multitude of other morbidities. Patients with untreated
sleep-disordered breathing have a higher mortality risk,
independent of age, gender, and body mass index (BMI).7
Pain causes sleep disorders such as wakefulness and sleep
apnea. There is a relationship between pain and sleep disturbances.8,9 Over 70% of patients with chronic pain disorders
report sleep disruption, and lack of restful sleep increases
hyperalgesia.8,9 By contrast, sleep rebound, especially in
non-REM sleep may have an analgesic effect.9 Hence, pain
induces sleep disorders and lack of sleep increases pain.
Opioids are widely used to treat chronic pain. In 1986
Portenoy and Foley published a review of 38 cases of CNCP
patients successfully treated with opioids,10 leading to wider
use in the management of CNCP. Today, it is ethically mandated to treat CNCP,11 resulting in a four-fold increase in opioid prescription during the 2000–2010 period. Unfortunately,
accidental opioid overdose, death, and dependency have
increased dramatically,12 reaching “epidemic” proportions13,14
and prescription opioids for chronic pain are recognized as
one of the roots of this problem.15,16
Opioid medications cause numerous unwanted and adverse
effects, apart from overdose. Of note, opioids have been shown
to decrease both central respiratory drive and the patency of the
upper airway. Hence, sleep-disordered breathing is observed in
patients on chronic opioid therapy. An observational study of
chronic pain patients on opioid therapy who received overnight
polysomnograms demonstrated an abnormal apnea-hypopnea
index (≥5 per hour) in 75% of patients, with a mixture of both
central and obstructive apneas.8 A dose-dependent relationship
between chronic opioid use and the development of a peculiar
pattern of respiration, consisting of central apneas and ataxic
breathing, has also been shown.17 Patients receiving sustainedrelease opioid medications have respiratory abnormalities
which are unique compared to opioid-free patients with OSA.
Longer, more severe hypoxia was observed in NREM compared to REM sleep. During NREM sleep, irregular respiratory
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pauses and gasping without periodicity were present. Nasal
positive airway pressure (CPAP) was shown to be ineffective
in these patients.18
Proper identification of chronic pain patients at a higher
risk for sleep-disordered breathing may be a difficult task
to accomplish due to the sedative effects of opioid medications, which overlap with vague symptoms of sleep apnea.
Screening questionnaires have been developed to identify
individuals at a higher risk for sleep apnea, including the
checklist of the American Society of Anesthesiology, the
STOP questionnaire (snoring, tiredness, observed apnea,
and high blood pressure), the STOP-Bang questionnaire
(STOP plus BMI, age, neck circumference, gender), and the
Epworth Sleepiness Scale. The STOP-Bang questionnaire is
a concise and easy-to-use, eight point, dichotomized (yes/
no) screening tool.19 In a systematic review of screening
questionnaires for sleep apnea, the STOP-Bang questionnaire
had the highest methodological quality and sensitivity.20 It
has been validated in different populations, including surgical
patients,21 hospitalized patients,22 and patients presenting to
a sleep disorders unit.23
The medical literature is limited in terms of the methods
used for the screening of patients on chronic opioids for sleep
apnea. Chronic opioid users’ awareness of their increased
risk for sleep apnea is also unknown. It is important to
identify those chronic pain patients who have sleep apnea,
so that early treatment can be initiated in order to improve
their quality of life and health status. The aims of this study
were to: 1) investigate risk of sleep apnea in the chronic
pain population, 2) assess knowledge and awareness of risk
for sleep apnea in patients, 3) evaluate the discussion and
assessment of sleep-disordered breathing with physicians as
a measure of their awareness, and 4) determine whether the
use of opioids increases the prevalence of sleep apnea in the
chronic pain population. This study was also intended to bring
to the attention of the sleep and pain medicine communities,
as well as general medical practitioners, the extent to which
sleep apnea may be under-diagnosed and under-treated in
the chronic pain population.

Participants and methods
Participants
The University of California Davis Pain Management Clinic
provides cutting-edge treatment of significant chronic pain
through a multidisciplinary approach. The clinical team
includes anesthesiologists, internists, and psychiatrists
with expertise in pain management to restore function and
decrease pain.
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The study protocol was approved by the UC Davis Institutional Review Board (IRB number 637877–1). The study
population was recruited from 357 consecutive patients presenting for their scheduled consultation at the Pain Management Clinic between September 9 and December 23, 2014.
Patients were invited to participate in an anonymous survey.
Subjects were excluded from the study if they declined to
participate or were under 18 years of age. Of the 357 patients
who were invited to participate, 305 met the inclusion criteria.
Most of the patients attending this specialist consultation
clinic who were on opioid therapy received their prescriptions
from external community providers, such as their primary
care physicians.

Chronic pain and STOP-Bang sleep questionnaire

The Epworth Sleepiness Scale (http://epworthsleepinessscale.com/about-the-ess/) is used to measure daytime
sleepiness by assessing the patient’s likelihood of falling
asleep under eight common scenarios. Likelihood is scored
between 0 (never) and 3 (high chance) with a total score
out of 24. A score greater than 10 is indicative of excessive
daytime sleepiness.24

Statistical analysis
Chi-squared test was used to study the association between
two categorical variables. A P-value <0.05 was considered
statistically significant. All analyses were performed with
SAS v9.4 (SAS Institute Inc., Cary, NC, USA).

Procedure

Results

All survey and questionnaire data collected were self-reported
by patients and considered anonymous. Thus, confirmation
of the disease status and medication relied on self-report.
Patients were asked to complete the survey on their own,
while waiting for their physician in treatment rooms.

Our study population had a mean age of 57.5+13.9 years.
The majority were female (66.1%) and Caucasian (81.2%)
(Table 1). The majority of the participants (72.2%) were
overweight or obese (BMI ≥25) (Table 1). Ninety-one point
nine percent (n=274) of the entire cohort was diagnosed
with a pain disorder of 6 months or longer. There were 202
(66.5%) patients on narcotic pain medication. Of the patients
who reported on their length of narcotic use, 75.7% (n=131)
of them were using narcotic pain medication for 6 months
or longer.
Table 2 reports on the prevalence of sleep apnea in pain
patients, and their awareness of it. According to the STOPBang assessment, overall 58.3% were positive (score ≥3) for
sleep apnea. There was no difference in prevalence between
opioid-treated and untreated patients. Most patients (90.7%)
were knowledgeable about sleep apnea, and this percentage
was not different in the opioid and non-opioid subgroups.
However, only approximately a third (35.9%) of all patients
had discussed their risk of sleep apnea with a health care
provider, and this was true even in the patients using opioids
who are at a theoretically greater risk. Furthermore, only
29.0% had ever been tested for sleep apnea and only 22.7%
of the whole of our chronic pain population had been treated.
A summary of outcomes for the Epworth Sleepiness
Scale and the STOP-Bang score screening questionnaires
is reported in Table 3. Among all subjects, 24.2% suffered
excessive daytime sleepiness (Epworth Sleepiness Scale
>10). Among opioid users, 25.9% (n=50) had an Epworth
Sleepiness Scale score greater than 10, compared with
22.2% (n=22) of the opioid non-users, a difference that
was not significant (P=0.58). According to the STOP-Bang
score, 58.3% were “positive” for sleep apnea with a score of
≥3. However, there was no significant difference (P=0.82)

Measures
The survey comprised eight pages and included diagnosis of
pain disorder (yes, no), consumption of narcotic pain medication including type and duration, and a detailed sleep history
(Supplementary material). The survey also included standardized validated questionnaires related to sleepiness and
sleep-disordered breathing. We also noted whether patients
reported having knowledge of sleep apnea, whether they had
discussed sleep apnea with a health care professional, and if
they had been tested for, diagnosed with or treated for sleep
apnea. Completion took approximately 5 minutes.
The STOP-Bang questionnaire, described in detail
elsewhere (http://www.stopbang.ca/osa/screening.php) is
comprised of eight yes/no questions relating to the risk
factors for OSA. Questions include snoring, daytime tiredness, observed apneas, high blood pressure, BMI (greater
than 35 kg/m2), age (greater than or equal to 50 years), neck
circumference (greater than 40 cm), and gender (male).
Measurement of height and weight, and the online calculation of BMI, were performed by the registered nurses as part
of the regular medical visit. A tape measure was included
in the survey, with instructions and anatomical guidelines
for measuring neck circumference. A trained research
assistant was present to assist with the neck circumference
measurement. A patient was considered at risk for OSA if
they had three or more positive responses on the STOPBang questionnaire.19
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Table 1 Demographic characteristics of opioid users and non-users
Demographic characteristics

Opioid users n=196

Non-opioid users n=101

Total n=297

Age (years)
Mean ± SD
(median, range)

56.6±14.0
(57, 19–90)

59.2±13.6
(60, 22–87)
P=NS

57.5±13.9
(58, 19–90)

Gender
Total
Female
Male
Not known

193*
133 (68.9%)
60 (31.1%)
3 (1.6%)

99*
60 (60.6%)
39 (39.4%)
2 (3.0%)
P=NS

292*
193 (66.1%)
99 (33.9%)
5 (1.7%)

Race
Total
Caucasian
African American
Asian
Hispanic
Native Hawaiian or Pacific Islander
American Indian or Alaskan Native
Prefer not to answer
Not known

188*
148 (78.7%)
13 (6.9%)
5 (2.7%)
17 (9.0%)
1 (0.5%)
2 (1.1%)
2 (1.1%)
8 (4.3%)

94*
81 (86.2%)
2 (2.1%)
4 (4.3%)
4 (4.3%)
0 (0.0%)
0 (0.0%)
3 (3.2%)
8 (8.5%)
P=NS

282*
229 (81.2%)
15 (5.3%)
9 (3.2%)
21 (7.5%)
1 (0.4%)
2 (0.7%)
5 (1.8%)
15 (5.3%)

BMI
Total
Underweight (BMI <18.5)
Healthy weight (BMI ≥18.5 and <25)
Overweight (BMI ≥25 and <30)
Obese (BMI ≥30)
Not known

192*
3 (1.6%)
48 (25.0%)
67 (34.9%)
67 (38.5%)
4 (2.1%)

99*
2 (2.0%)
28 (28.3%)
33 (33.3%)
36 (36.4%)
3 (3.0%)
P=NS

291*
5 (1.7%)
76 (26.1%)
100 (34.4%)
110 (37.8%)
6 (2.1%)

Diagnosed or treated for pain disorder of ≥6 months
Total
Yes
No

196
187 (95.4%)
9 (4.6%)

101
87 (86.1%)
15 (14.9%)
P=0.002

297
274 (91.9%)
24 (8.1%)

Notes: Not all participants answered all questions. The number of respondents (*) in each section are shown. Missing answers are given as “not known” in the table. P,
significance of difference between opioid and non-opioid users.
Abbreviation: NS, not significant.

between the STOP-Bang score of ≥3 in opioid users (59.2%)
and non-users (56.4%). In fact, there was no difference in
STOP-Bang score at any level between opioid users and
non-users (P=0.84).
Figure 1 depicts the use of different opioid medications amongst our study population. The majority of our
subjects were either taking hydrocodone (39.8%, n=121) or
oxycodone (20.1%, n=61). The doses being taken were not
recorded because of concern that patients’ recollection may
be unreliable. Concomitant use of hypnotics was reported in
24.7% (n=50) of opioid users, compared to 14.6% (n=14) of
opioid non-users.
Some of the patients were taking hypnotic medications.
The survey asked about use of hypnotic medications, but did
not request the dose. Of the opioid users, 24.7% were taking a
hypnotic while 14.6% of non-users were, too. This difference
220
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did achieve minimal statistical significance (P=0.046) but the
frequency of OSA, according to the STOP-Bang score, did
not differ in the patient groups using opioids vs those using
opioids plus hypnotics.

Discussion
This survey found that a significant percentage of patients
with CNCP are at risk for OSA. The proportion of CNCP
patients screening positive on the STOP-Bang questionnaire
for OSA is much higher than the prevalence reported in the
general population. Given the relationship between chronic
pain disorders and sleep disruption,8,9 it is understandable
why almost 60% of our cohort screened at risk for sleep
apnea using the STOP-Bang questionnaire. Remarkably,
given the elevated risk associated with chronic pain, only
approximately 35% of patients had discussed their apnea risk
Nature and Science of Sleep 2018:10
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Table 2 Patient awareness of sleep apnea risks
STOP-Bang (score ≥3)
Positive
Negative
Do you know what sleep apnea is?
Yes
No
Have you or your health care provider ever discussed your risk of sleep apnea?
Yes
No
Have you ever been tested for sleep apnea?
Yes
No
Have you ever undergone a sleep study (polysomnogram)?
Yes
No
Have you ever been diagnosed with sleep apnea?
Yes
No
Have you ever been treated with positive airway pressure (CPAP or BiPAP)?
Yes
No

Opioid users

Opioid non-users

Total

n=196
116 (59.2%)
80 (40.8%)
n=191*
174 (91.1%)
17 (8.9%)
n=192*
72 (37.5%)
120 (62.5%)
n=192*
59 (30.7%)
133 (69.3%)
n=192*
62 (32.3%)
130 (67.7%)
n=192*
42 (21.9%)
150 (78.1%)
n=192*
42 (21.9%)
150 (78.1%)

n=101
57 (56.4%)
44 (43.6%)
n=99*
89 (89.9%)
10 (10.0%)
n=98*
32 (32.6%)
66 (67.4%)
n=98*
25 (25.8%)
73 (74.5%)
n=99*
27 (27.3%)
72 (72.7%)
n=99*
24 (24.2%)
75 (75.8%)
n=97*
19 (19.6%)
78 (80.4%)

n=297
173 (58.3%)
124 (41.7%)
n=290*
263 (90.7%)
27 (9.3%)
n=290*
104 (35.9%)
186 (64.1%)
n=290*
84 (29.0%)
206 (71.0%)
n=291*
89 (30.6%)
202 (69.4%)
n=291*
66 (22.7%)
225 (77.3%)
n=289*
61 (21.1%)
228 (78.9%)

Notes: None of the differences between groups were statistically significant by Chi-squared analysis. P-values ranged from 0.35 to 0.74. Not all participants answered all
questions. The number of respondents (*) to each question is given.

Table 3 Summary of outcomes for Epworth and STOP-Bang screening questionnaires
Screening questionnaire

Opioid user group n=196

Opioid non-user group n=101

Total n=297

Epworth Sleepiness Scale score – median (range)

7 (0–22) n=192*
50/192* (25.9%)
3 (1.5%)
24 (12.3%)
53 (27.0%)
49 (25.0%)
29 (14.8%)
19 (9.7%)
14 (7.1%)
4 (2.0%)
1 (0.5%)

7 (0–23) n=99*
22/99* (22.2%)
0 (0.0%)
13 (12.9%)
31 (30.7%)
17 (16.8%)
22 (21.8%)
6 (5.9%)
8 (7.9%)
4 (4.0%)
0 (0.0%)

7 (0–23) n=291*
72/291* (24.2%)
3 (1.0%)
37 (12.5%)
84 (28.3%)
66 (22.2%)
51 (17.2%)
25 (8.4%)
22 (7.4%)
8 (2.7%)
1 (0.3%)

Epworth Scale score >10 (excessive daytime sleepiness)
STOP-Bang score 0
STOP-Bang score 1
STOP-Bang score 2
STOP-Bang score 3
STOP-Bang score 4
STOP-Bang score 5
STOP-Bang score 6
STOP-Bang score 7
STOP-Bang score 8

Notes: There were no statistically significant differences between the opioid user and non-user groups on the Epworth Sleepiness Scale (P=0.59) or for STOP-Bang positivity
(P=0.84). *Not all participants answered all questions.

with their health care provider. The implication is that many
of these individuals may be undiagnosed and unrecognized,
supported by the fact that fewer than a quarter of our population reported having been diagnosed and treated for sleep
apnea by a physician. Although the screening questionnaires
are not independently sufficient to make a clinical diagnosis,
the discrepancy between the percentage screening at risk and
the percentage reporting being diagnosed by a medical provider is striking. Given all of the health repercussions, such
as cardiovascular and cerebrovascular disease, that come with
a diagnosis of sleep apnea, special attention to the increased
risk in the chronic pain population is warranted.
Nature and Science of Sleep 2018:10

In recent years it has become common to treat chronic
pain with opioids. However, opioid use is associated with
substantial side effects and approximately 80% of individuals
prescribed opioids will experience at least one side effect.25
In addition, patients using opioids may suffer respiratory
depression,26 endocrine effects, addiction, and fatal overdose. Paradoxically, patients may experience opioid-induced
hyperalgesia27 with worsening pain in response to certain
types of pain stimuli.
Opioids inhibit the basic sleep-wake mechanisms by
inhibiting transmission through central cholinergic and
adenosinergic pathways.28 In addition to central apnea, opisubmit your manuscript | www.dovepress.com
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Figure 1 Opiate drug distribution among subjects.

oids can contribute to OSA by deeply relaxing the tissues of
the upper airway leading to mechanical obstruction.29 Sleepdisordered breathing may increase the sensitivity of both
central and airway effects of opioids, while sleep disruption,
intermittent hypoxemia, and systemic inflammation influence
pain behavior and sensitivity to opioids.30
Given the association between opioid treatment and sleepdisordered breathing, it was expected that our CNCP patients
using opioids would be at greater risk of sleep apnea. Against
expectation, there was no difference in STOP-Bang positivity
(score ≥3) between opioid users and non-users. This prompts
the question whether opioids really do increase the risk of
OSA in chronic pain patients, and whether the STOP-Bang
questionnaire is appropriate to identify an increased risk for
sleep apnea, in particular OSA, in opioid users. The choice
and dose of opioid medication were “given to effect”. In
hindsight, data collection of opioid dose as well as which
medication, might have revealed a relationship between
higher “morphine equivalent doses” and an increased frequency of sleep-disordered breathing. If such a relationship
were to exist, then a case could be made for mandatory
sleep-disordered breathing screening in all patients taking
high morphine equivalent doses (for example, exceeding
200 mg/day).
One possibility is that there may be co-occurrence of
central apnea and obstructive apnea with opioid use. The
questions on the STOP-Bang questionnaire is useful in
screening for obstructive sleep apnea rather than central sleep
apnea. Indeed, these factors may well be absent in a person
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experiencing CSA. Therefore, the STOP-Bang questionnaire
may not be the best instrument to identify increased total
apnea risk due to opioid therapy. However, daytime sleepiness which could be due to either central or peripheral apnea
mechanisms, was the same in both opioid user and non-user
patients. On the Epworth Sleepiness Scale, approximately
25% of both opioid users and non-users scored >10 associated with “excessive daytime sleepiness”,24 perhaps suggesting that there is not an excess of central apnea in the opioid
using patients.
If the measures contributing to the STOP-Bang score
were more prevalent in the non-opioid group, this might
have hidden the effect of opioids on apnea. However, patient
demographics were extremely similar in both the opioid and
non-opioid user groups. Age, gender, and BMI, all known to
be associated with OSA2–4 and addressed by the questions
in the Bang section of the questionnaire, were not different between opioid users and non-users (Table 1). There
were no significant differences in any of these demographic
parameters that might explain why the opioid user group
did not have a higher proportion of patients with a positive
STOP-Bang score.
Concomitant use of hypnotic medications such as benzodiazepines has been shown to worsen sleep apnea. They
have the potential to cause complete OSA in heavy snorers
or short repetitive CSAs.31 When used in conjunction with
opioid medications these effects can be even more pronounced, making this a potentially lethal combination. In
this survey, concomitant use of opioids and a hypnotic agent
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did not appear to increase the risk of OSA compared with
use of opioids alone.
One possibility for the finding that the STOP-Bang questionnaire did not differentiate opioid users and non-users is
that it did not distinguish the severity of apnea risk. In this
study the STOP-Bang scores were dichotomized, by design,
into positive or negative with a cut-off threshold score of ≥3.
However, increasing STOP-Bang scores reportedly predict
the probabilities from none through moderate to severe
OSA.19 In this study cohort, the demographic data showed
that the risk of OSA is high with older, overweight patients
already scoring high on the Bang section of the questionnaire. An analysis of the STOP-Bang scores at all levels,
from 0 to 8, showed no significant association with opioid
use (Table 3), suggesting that the severity of OSA in opioid
users is not greater than in opioid non-users.
Approximately one third of both the opioid-using and
non-using patients had discussed the risk of sleep apnea with
a health care provider. Fewer had been tested for sleep apnea.
Overall, only approximately 20% of patients were diagnosed
and treated for sleep apnea. These observations suggest a
knowledge gap in patients being prescribed opioids when it
comes to being warned of sleep-disordered breathing as a side
effect. More reliable approaches can be designed to educate
patients about the side effects of opioids, including sleep
disorders and addiction,15,16 to ensure a true understanding
of the risks and benefits of opioids. Previous studies have
estimated the risk of sleep apnea in the chronic pain population using opioids to be as high as 75%. The low percentages
of patients in this survey tested and diagnosed may point to
incomplete screening, testing, and diagnosis in this high-risk
patient population. This large disparity between patients at
risk and patients being diagnosed indicates that a very high
percentage of opioid-using and non-using patients may be
undiagnosed and untreated for sleep apnea.
We acknowledge several possible limitations to this study.
The first limitation is that our study population was from an
academic hospital and may not be representative of the pain
population as a whole. Patients attending academic hospitals
may be wealthier and better insured than the general pain population. Patients in this particular pain clinic were receiving
consultation while prescribing was generally under the auspice
of longitudinal providers such as the primary care clinicians.
Another potential limitation of our study was the survey
design. All information was anonymously self-reported by
subjects and not confirmed by health records, which may lead
to a self-report bias. Although the STOP-Bang OSA screening
questionnaire has been validated in several populations, it has

Nature and Science of Sleep 2018:10

Chronic pain and STOP-Bang sleep questionnaire

not been validated in the chronic pain population. This is a
major limitation in that the STOP-Bang questionnaire, as generally applied, requires only three positive responses to define
a high risk of OSA. In our population, many were older, overweight, and likely to have an increased neck circumference,
reducing the sensitivity of the STOP-Bang score. However,
even a comparison of STOP-Bang scores across the full range
(from 0 to 8) did not reveal a difference in the frequency of
OSA between opioid users and non-users. A clinician neither
separately interviewed nor examined the subjects to confirm a
diagnosis of sleep apnea, nor was polysomnography included
as part of the study to validate the findings of the sleep apnea
questionnaire. Although the STOP-Bang questionnaire has a
relatively high sensitivity and specificity for the identification
of OSA, polysomnography is the “gold standard” since the
STOP-Bang questionnaire cannot identify other forms of
sleep-disordered breathing such as CSA.
In conclusion, a large percentage of chronic pain subjects
screened positive for OSA, regardless of opioid use. Many had
never discussed their risk of sleep apnea with a health care
professional nor were they personally aware that opioids may
have increased their risk for sleep apnea. Given the estimated
high prevalence of sleep apnea in patients on chronic opioids,
our study indicates that a large proportion of our patients were
undiagnosed and untreated, raising significant patient safety
concerns. These findings suggest that physicians prescribing
opioids need to be more conscious of the serious risks for
sleep-disordered breathing leading to sleep apnea. There is a
need for both greater awareness of both CSA and OSA in the
chronic pain population and a proactive approach to provider
discussion about sleep disorders. Education for prescribers,
who are mostly in general medical practices, is greatly needed.
Our initial study with the STOP-Bang questionnaire showed
that it is simple to use and does identify patients at risk of sleep
apnea. Future research is needed to validate a screening tool to
properly identify those chronic pain patients at increased risk
of sleep apnea, so that they can be appropriately tested with
polysomnography and treated if their diagnosis is confirmed.
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